Proteomic and phosphoproteomic analyses of myectomy tissue reveals difference between sarcomeric and genotype-negative hypertrophic cardiomyopathy

Figures

• 

  Figure 1. Comparison of gene ontology (GO) biological processes altered between HCMSarc and HCMNeg. (A) Most up-regulated gene ontology (GO) biological processes in the proteome using gene set enrichment analysis (GSEA). (B) Most down-regulated GO biological processes in proteome using GSEA. (C) Most altered GO biological processes in phosphoproteome using GSEA.

• 

  Figure 2. Comparison of pathways altered between HCMSarc and HCMNeg. (A) Most statistically altered pathways (largest-log [BH p-value]) in proteome. (B) Top up- and down-regulated pathways in proteome. (C) Most statistically altered phosphorylation (largest-log [BH p-value]) of pathways. (D) Top activated and inactivated pathways based on phosphorylation (z-score ≥|1|). *Regulation of the epithelial mesenchymal transition by growth factors pathway was shortened.

• 

  Figure 3. Altered diseases and functions in proteome and phosphoproteome identified using ingenuity pathway analysis.

• 

  Figure 4. Commonalities and differences in the proteome and phosphoproteome of HCMSarc and HCMNeg. (A) Venn diagram comparing differentially expressed proteins (DEPs) between different comparisons. (B) Venn diagram comparing differentially phosphorylated proteins (DPPs) between different comparisons. (C) Heatmap showing directionality of differentially expressed proteins (DEPs) altered in both HCMSarc and HCMNeg compared with controls. (D) Heatmap showing directionality of differentially phosphorylated proteins (DPPs) altered in both HCMSarc and HCMNeg compared with controls. Log2fc, log2 fold change.

• 

  Figure 5. Commonalities and differences in the proteome and phosphoproteome of HCMSarc and HCMNeg continued. (A) Venn diagram comparing pathways altered in proteome between different comparisons. (B) Venn diagram comparing pathways with altered phosphorylation between different comparisons. (C) Heatmap showing directionality of pathways altered in both HCMSarc and HCMNeg compared with controls. (D) Heatmap showing directionality of phosphorylated pathways altered in both HCMSarc and HCMNeg compared with controls.

• 

  Figure 6. Proteome of sarcomere-positive HCM and sarcomere-negative HCM have differences in disease specific pathways with most differences between them being more severe in sarcomere-positive HCM.